Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001882132 | SCV002166609 | pathogenic | not provided | 2021-04-27 | criteria provided, single submitter | clinical testing | This variant disrupts the C-terminus of the EYS protein. Other variant(s) that disrupt this region (p.Tyr3135*) have been determined to be pathogenic (PMID: 18976725, 31074760, 29159838, 30337596). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with EYS-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change creates a premature translational stop signal (p.Asn3080Leufs*2) in the EYS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 65 amino acid(s) of the EYS protein. For these reasons, this variant has been classified as Pathogenic. |
Baylor Genetics | RCV004571551 | SCV005060483 | likely pathogenic | Retinitis pigmentosa 25 | 2024-02-07 | criteria provided, single submitter | clinical testing |